ADZENYS Drug Patent Profile
✉ Email this page to a colleague
When do Adzenys patents expire, and when can generic versions of Adzenys launch?
Adzenys is a drug marketed by Neos Theraps Inc and Neos Theraps and is included in two NDAs. There are five patents protecting this drug.
The generic ingredient in ADZENYS is amphetamine. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adzenys
A generic version of ADZENYS was approved as amphetamine by ACTAVIS LABS FL INC on June 22nd, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ADZENYS?
- What are the global sales for ADZENYS?
- What is Average Wholesale Price for ADZENYS?
Summary for ADZENYS
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for ADZENYS |
| DailyMed Link: | ADZENYS at DailyMed |
US Patents and Regulatory Information for ADZENYS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | AB | RX | Yes | Yes | 9,265,737 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-005 | Jan 27, 2016 | AB | RX | Yes | No | 9,265,737 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | AB | RX | Yes | Yes | 8,709,491 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Neos Theraps | ADZENYS XR-ODT | amphetamine | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 204326-006 | Jan 27, 2016 | AB | RX | Yes | Yes | 9,839,619 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
